• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

长期 AAV9 介导的 SMN 过表达在感觉运动回路中获得毒性功能。

Gain of toxic function by long-term AAV9-mediated SMN overexpression in the sensorimotor circuit.

机构信息

Center for Motor Neuron Biology and Disease, Columbia University, New York, NY, USA.

Department of Pathology and Cell Biology, Columbia University, New York, NY, USA.

出版信息

Nat Neurosci. 2021 Jul;24(7):930-940. doi: 10.1038/s41593-021-00827-3. Epub 2021 Apr 1.

DOI:10.1038/s41593-021-00827-3
PMID:33795885
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8254787/
Abstract

The neurodegenerative disease spinal muscular atrophy (SMA) is caused by deficiency in the survival motor neuron (SMN) protein. Currently approved SMA treatments aim to restore SMN, but the potential for SMN expression beyond physiological levels is a unique feature of adeno-associated virus serotype 9 (AAV9)-SMN gene therapy. Here, we show that long-term AAV9-mediated SMN overexpression in mouse models induces dose-dependent, late-onset motor dysfunction associated with loss of proprioceptive synapses and neurodegeneration. Mechanistically, aggregation of overexpressed SMN in the cytoplasm of motor circuit neurons sequesters components of small nuclear ribonucleoproteins, leading to splicing dysregulation and widespread transcriptome abnormalities with prominent signatures of neuroinflammation and the innate immune response. Thus, long-term SMN overexpression interferes with RNA regulation and triggers SMA-like pathogenic events through toxic gain-of-function mechanisms. These unanticipated, SMN-dependent and neuron-specific liabilities warrant caution on the long-term safety of treating individuals with SMA with AAV9-SMN and the risks of uncontrolled protein expression by gene therapy.

摘要

神经退行性疾病脊髓性肌萎缩症(SMA)是由运动神经元存活(SMN)蛋白缺乏引起的。目前批准的 SMA 治疗方法旨在恢复 SMN,但腺相关病毒血清型 9(AAV9)-SMN 基因治疗的一个独特特征是 SMN 表达超过生理水平的潜力。在这里,我们表明,在小鼠模型中长期 AAV9 介导的 SMN 过表达会导致剂量依赖性的运动功能障碍,其特征是与本体感受突触丧失和神经退行性变相关的迟发性发病。从机制上讲,过表达的 SMN 在运动回路神经元细胞质中的聚集会隔离小核核糖核蛋白的成分,导致剪接失调和广泛的转录组异常,具有明显的神经炎症和先天免疫反应特征。因此,长期 SMN 过表达会干扰 RNA 调节,并通过毒性获得功能机制引发类似 SMA 的致病事件。这些意想不到的、依赖 SMN 和神经元特异性的缺陷,使得使用 AAV9-SMN 治疗 SMA 患者的长期安全性以及基因治疗中不受控制的蛋白质表达的风险需要谨慎对待。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b95f/8254787/58eb66c64565/nihms-1677475-f0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b95f/8254787/2239fefd0598/nihms-1677475-f0007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b95f/8254787/8c0644438778/nihms-1677475-f0008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b95f/8254787/f2c354347189/nihms-1677475-f0009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b95f/8254787/2ac53e6ebcb4/nihms-1677475-f0010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b95f/8254787/8b95a603a578/nihms-1677475-f0011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b95f/8254787/5b3fe5fef322/nihms-1677475-f0012.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b95f/8254787/285eb4d5a826/nihms-1677475-f0013.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b95f/8254787/dd3f473694df/nihms-1677475-f0014.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b95f/8254787/bc86a873623f/nihms-1677475-f0015.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b95f/8254787/dba230e08508/nihms-1677475-f0016.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b95f/8254787/57f0c4f3d545/nihms-1677475-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b95f/8254787/098cbe1391dd/nihms-1677475-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b95f/8254787/54e06ba84209/nihms-1677475-f0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b95f/8254787/00ddd9659ec5/nihms-1677475-f0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b95f/8254787/7b856838b175/nihms-1677475-f0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b95f/8254787/58eb66c64565/nihms-1677475-f0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b95f/8254787/2239fefd0598/nihms-1677475-f0007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b95f/8254787/8c0644438778/nihms-1677475-f0008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b95f/8254787/f2c354347189/nihms-1677475-f0009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b95f/8254787/2ac53e6ebcb4/nihms-1677475-f0010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b95f/8254787/8b95a603a578/nihms-1677475-f0011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b95f/8254787/5b3fe5fef322/nihms-1677475-f0012.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b95f/8254787/285eb4d5a826/nihms-1677475-f0013.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b95f/8254787/dd3f473694df/nihms-1677475-f0014.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b95f/8254787/bc86a873623f/nihms-1677475-f0015.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b95f/8254787/dba230e08508/nihms-1677475-f0016.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b95f/8254787/57f0c4f3d545/nihms-1677475-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b95f/8254787/098cbe1391dd/nihms-1677475-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b95f/8254787/54e06ba84209/nihms-1677475-f0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b95f/8254787/00ddd9659ec5/nihms-1677475-f0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b95f/8254787/7b856838b175/nihms-1677475-f0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b95f/8254787/58eb66c64565/nihms-1677475-f0006.jpg

相似文献

1
Gain of toxic function by long-term AAV9-mediated SMN overexpression in the sensorimotor circuit.长期 AAV9 介导的 SMN 过表达在感觉运动回路中获得毒性功能。
Nat Neurosci. 2021 Jul;24(7):930-940. doi: 10.1038/s41593-021-00827-3. Epub 2021 Apr 1.
2
AAV9-Mediated Expression of SMN Restricted to Neurons Does Not Rescue the Spinal Muscular Atrophy Phenotype in Mice.腺相关病毒 9 介导的神经元特异性表达 SMN 不能拯救小鼠的脊髓性肌萎缩表型。
Mol Ther. 2020 Aug 5;28(8):1887-1901. doi: 10.1016/j.ymthe.2020.05.011. Epub 2020 May 15.
3
Improved therapeutic approach for spinal muscular atrophy via ubiquitination-resistant survival motor neuron variant.通过抗泛素化存活运动神经元变体改善脊髓性肌萎缩症的治疗方法。
J Cachexia Sarcopenia Muscle. 2024 Aug;15(4):1404-1417. doi: 10.1002/jcsm.13486. Epub 2024 Apr 22.
4
Stasimon Contributes to the Loss of Sensory Synapses and Motor Neuron Death in a Mouse Model of Spinal Muscular Atrophy.Stasimon 导致脊髓性肌萎缩症小鼠模型中感觉突触丧失和运动神经元死亡。
Cell Rep. 2019 Dec 17;29(12):3885-3901.e5. doi: 10.1016/j.celrep.2019.11.058.
5
AAV9-Stathmin1 gene delivery improves disease phenotype in an intermediate mouse model of spinal muscular atrophy.腺相关病毒 9-微管相关蛋白 1 基因传递改善中间型脊髓性肌萎缩症小鼠模型的疾病表型。
Hum Mol Genet. 2019 Nov 15;28(22):3742-3754. doi: 10.1093/hmg/ddz188.
6
Improving single injection CSF delivery of AAV9-mediated gene therapy for SMA: a dose-response study in mice and nonhuman primates.改善单剂量注射脑脊液递送AAV9介导的脊髓性肌萎缩症基因疗法:小鼠和非人灵长类动物的剂量反应研究
Mol Ther. 2015 Mar;23(3):477-87. doi: 10.1038/mt.2014.210. Epub 2014 Oct 31.
7
Translational fidelity of intrathecal delivery of self-complementary AAV9-survival motor neuron 1 for spinal muscular atrophy.鞘内注射自我互补型 AAV9-存活运动神经元 1 治疗脊髓性肌萎缩症的转译忠实度。
Hum Gene Ther. 2014 Jul;25(7):619-30. doi: 10.1089/hum.2014.011. Epub 2014 Apr 28.
8
Severe Toxicity in Nonhuman Primates and Piglets Following High-Dose Intravenous Administration of an Adeno-Associated Virus Vector Expressing Human SMN.在高剂量静脉内给予表达人 SMN 的腺相关病毒载体后,非人类灵长类动物和仔猪出现严重毒性。
Hum Gene Ther. 2018 Mar;29(3):285-298. doi: 10.1089/hum.2018.015. Epub 2018 Feb 12.
9
Calpain Inhibition Increases SMN Protein in Spinal Cord Motoneurons and Ameliorates the Spinal Muscular Atrophy Phenotype in Mice.钙蛋白酶抑制可增加脊髓运动神经元中的 SMN 蛋白,并改善小鼠的脊髓性肌萎缩表型。
Mol Neurobiol. 2019 Jun;56(6):4414-4427. doi: 10.1007/s12035-018-1379-z. Epub 2018 Oct 16.
10
Limited phenotypic effects of selectively augmenting the SMN protein in the neurons of a mouse model of severe spinal muscular atrophy.在严重脊髓性肌肉萎缩症的小鼠模型中,选择性增强神经元中的 SMN 蛋白,其表型效应有限。
PLoS One. 2012;7(9):e46353. doi: 10.1371/journal.pone.0046353. Epub 2012 Sep 27.

引用本文的文献

1
Identification of p38 MAPK inhibition as a neuroprotective strategy for combinatorial SMA therapy.确定p38丝裂原活化蛋白激酶抑制作为脊髓性肌萎缩症联合治疗的神经保护策略。
EMBO Mol Med. 2025 Sep 8. doi: 10.1038/s44321-025-00303-6.
2
Safety through design: Expanding options for spinal muscular atrophy gene therapy.通过设计实现安全:拓展脊髓性肌萎缩症基因治疗的选择
Mol Ther Methods Clin Dev. 2025 Aug 19;33(3):101550. doi: 10.1016/j.omtm.2025.101550. eCollection 2025 Sep 11.
3
AAV-based delivery of RNAi targeting ataxin-2 improves survival and pathology in TDP-43 mice.

本文引用的文献

1
Stasimon Contributes to the Loss of Sensory Synapses and Motor Neuron Death in a Mouse Model of Spinal Muscular Atrophy.Stasimon 导致脊髓性肌萎缩症小鼠模型中感觉突触丧失和运动神经元死亡。
Cell Rep. 2019 Dec 17;29(12):3885-3901.e5. doi: 10.1016/j.celrep.2019.11.058.
2
The Classical Complement Pathway Mediates Microglia-Dependent Remodeling of Spinal Motor Circuits during Development and in SMA.经典补体途径介导发育过程中和 SMA 中脊髓运动回路的小胶质细胞依赖性重塑。
Cell Rep. 2019 Dec 3;29(10):3087-3100.e7. doi: 10.1016/j.celrep.2019.11.013.
3
Disruption of RNA Metabolism in Neurological Diseases and Emerging Therapeutic Interventions.
基于腺相关病毒(AAV)递送靶向ataxin-2的RNA干扰可改善TDP-43小鼠的存活率并减轻其病理变化。
Nat Commun. 2025 Jun 25;16(1):5334. doi: 10.1038/s41467-025-60497-8.
4
Novel drug-inducible CRISPRa/i systems for rapid and reversible manipulation of gene transcription.用于快速可逆地操纵基因转录的新型药物诱导型CRISPRa/i系统。
Cell Mol Life Sci. 2025 Jun 23;82(1):249. doi: 10.1007/s00018-025-05786-7.
5
Development of circular AAV cargos for targeted seamless insertion with large serine integrases.用于通过大型丝氨酸整合酶进行靶向无缝插入的环状腺相关病毒载体的开发。
Mol Ther Methods Clin Dev. 2025 May 14;33(2):101490. doi: 10.1016/j.omtm.2025.101490. eCollection 2025 Jun 12.
6
Efficacy and preliminary safety assessment of EXG001-307 AAV gene therapy for spinal muscular atrophy.EXG001-307腺相关病毒基因疗法治疗脊髓性肌萎缩症的疗效及初步安全性评估
Mol Ther Methods Clin Dev. 2025 Apr 18;33(2):101475. doi: 10.1016/j.omtm.2025.101475. eCollection 2025 Jun 12.
7
Programmable gene insertion in human cells with a laboratory-evolved CRISPR-associated transposase.利用实验室进化的CRISPR相关转座酶在人类细胞中进行可编程基因插入。
Science. 2025 May 15;388(6748):eadt5199. doi: 10.1126/science.adt5199.
8
Large-scale discovery of potent, compact and erythroid specific enhancers for gene therapy vectors.用于基因治疗载体的强效、紧凑且红细胞特异性增强子的大规模发现。
Nat Commun. 2025 May 9;16(1):4325. doi: 10.1038/s41467-025-59235-x.
9
Current clinical applications of AAV-mediated gene therapy.腺相关病毒介导的基因治疗的当前临床应用。
Mol Ther. 2025 Jun 4;33(6):2479-2516. doi: 10.1016/j.ymthe.2025.04.045. Epub 2025 May 5.
10
Developing a gene therapy for Charcot-Marie-Tooth disease: progress and challenges.开发用于治疗夏科-马里-图思病的基因疗法:进展与挑战。
Regen Med. 2025 Apr 12:1-9. doi: 10.1080/17460751.2025.2491257.
神经疾病中 RNA 代谢的紊乱及新兴治疗干预措施
Neuron. 2019 Apr 17;102(2):294-320. doi: 10.1016/j.neuron.2019.03.014.
4
Health outcomes in spinal muscular atrophy type 1 following AVXS-101 gene replacement therapy.脊髓性肌萎缩症 1 型接受 AVXS-101 基因治疗后的健康结果。
Pediatr Pulmonol. 2019 Feb;54(2):179-185. doi: 10.1002/ppul.24203. Epub 2018 Dec 12.
5
Dysregulation of Mdm2 and Mdm4 alternative splicing underlies motor neuron death in spinal muscular atrophy.Mdm2 和 Mdm4 剪接异构体失调是脊髓性肌萎缩症运动神经元死亡的基础。
Genes Dev. 2018 Aug 1;32(15-16):1045-1059. doi: 10.1101/gad.316059.118. Epub 2018 Jul 16.
6
New tricks for an ancient system: Physiological and pathological roles of complement in the CNS.新技巧用于古老系统:补体在中枢神经系统中的生理和病理作用。
Mol Immunol. 2018 Oct;102:3-13. doi: 10.1016/j.molimm.2018.06.264. Epub 2018 Jun 27.
7
Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy.依库珠单抗治疗晚发性脊髓性肌萎缩症的疗效观察:一项随机、双盲、安慰剂对照 3 期试验
N Engl J Med. 2018 Feb 15;378(7):625-635. doi: 10.1056/NEJMoa1710504.
8
The Neurotropic Properties of AAV-PHP.B Are Limited to C57BL/6J Mice.AAV-PHP.B 的神经嗜性仅限于 C57BL/6J 小鼠。
Mol Ther. 2018 Mar 7;26(3):664-668. doi: 10.1016/j.ymthe.2018.01.018. Epub 2018 Feb 2.
9
Severe Toxicity in Nonhuman Primates and Piglets Following High-Dose Intravenous Administration of an Adeno-Associated Virus Vector Expressing Human SMN.在高剂量静脉内给予表达人 SMN 的腺相关病毒载体后,非人类灵长类动物和仔猪出现严重毒性。
Hum Gene Ther. 2018 Mar;29(3):285-298. doi: 10.1089/hum.2018.015. Epub 2018 Feb 12.
10
Converging Mechanisms of p53 Activation Drive Motor Neuron Degeneration in Spinal Muscular Atrophy.p53 激活的汇聚机制导致脊髓性肌萎缩症中的运动神经元变性。
Cell Rep. 2017 Dec 26;21(13):3767-3780. doi: 10.1016/j.celrep.2017.12.003.